UK – NICE sticks to Zytiga rejection

NICE will not be recommending Janssen's Zytiga (abiraterone acetate) with prednisone or prednisolone plus androgen deprivation therapy (ADT), within its marketing authorisation, for treating newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adults.

Around 4,000 men newly diagnosed with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) would have been eligible for treatment abiraterone acetate in combination with prednisone/prednisolone and ADT.

Currently, men first diagnosed with advanced prostate cancer are treated with hormone therapy with docetaxel chemotherapy, or hormone therapy on its own, but because chemotherapy can come with serious side effects, around three quarters are unable to tolerate it or choose not to have it…